Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US and Europe.
The financial terms of the agreement include an initial payment of USD 25 million from Viatris to Lexicon, with further commitments to milestone payments tied to regulatory and sales achievements, and tiered royalties that range from the low-double-digit to upper-teens percentage on annual net sales.
Sotagliflozin, a dual SGLT2 and SGLT1 inhibitor, received marketing approval in the United States in May of the previous year. It is indicated for reducing the risk of cardiogenic death and hospitalization due to heart failure, as well as acute heart failure, in adult patients with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.- Flcube.com
